Institutional members access full text with Ovid®

Share this article on:

Progress in HIV-1 vaccine development

Haynes, Barton F.a; McElrath, M. Julianab

Current Opinion in HIV and AIDS: July 2013 - Volume 8 - Issue 4 - p 326–332
doi: 10.1097/COH.0b013e328361d178
THIRTY YEARS OF HIV AND AIDS: Edited by David A. Cooper and Giuseppe Pantaleo

Purpose of review In this review, examples of recent progress in HIV-1 vaccine research are discussed.

Recent findings New insights from the immune correlates analyses of the RV144 efficacy trial have accelerated vaccine development with leads to follow in nonhuman primate studies and improved vaccine designs. Several new vaccine vector approaches offer promise in the exquisite control of acute infection and in improving the breadth of T-cell responses. New targets of broadly neutralizing antibodies (BnAbs) have been elucidated, and improved understanding of how the human host controls BnAb development have emerged from BnAb knock-in mice and from analyses of BnAb maturation and virus evolution in individuals followed from the time of HIV-1 transmission to BnAb induction.

Summary Based on these observations, it is clear that the development of a successful HIV-1 vaccine will require new vaccine approaches and iterative testing of immunogens in well designed animal and human trials.

aDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina

bVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington D.C., USA

Correspondence to Barton F. Haynes, MD, Duke Human Vaccine Institute, 106 Research Drive, Medical Sciences Research Building II, Rm. 4087, Durham, NC 27710, USA. Tel: +1 919 684 5279; fax: +1 919 684 5230; E-mail: hayne002@mc.duke.edu

© 2013 Lippincott Williams & Wilkins, Inc.